Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ValiRx trial group receives cancer treatment with no adverse effects

VAL201 is being developed to treat hormone-resistant prostate cancer and is currently undergoing a phase I/II study.
ValiRx trial group receives cancer treatment with no adverse effects
VAL201 is being developed to tackle prostate cancer.

ValiRx (LON:VAL) said a further group of patients receiving VAL201 have completed the clinical trial dosing sequence with no significant adverse effects.

VAL201 is being developed to treat hormone-resistant prostate cancer and is currently undergoing a phase I/II study.

The latest feedback echoes that from an earlier cohort on a lower dose of the medication. ValiRx will now be allowed to increase the amount of VAL201 administered to cancer sufferers one last time to assess its impact.

“The company believes that being able to dose patients at levels and with a frequency that matches the pre-clinical validated amounts that are therapeutically relevant, represents another important milestone,” ValiRx said in a short stock exchange statement.

The firm will provide updates as the trial progresses. Eagerly awaited will be any hint of efficacy. Researchers saw “tumour modulating effects” pre-clinically and they have been “hinted at during the in-human stage”.

Ian_55ae0ddd437b7.jpg
Why Invest In ValiRx Plc? Read More Here

Register here to be notified of future VAL Company articles
View full VAL profile

ValiRx Plc Timeline

Big Picture
May 19 2016

Related Articles

World map made out of drugs
April 12 2016
The pharma services and drug development group has hit key milestones in the last year.
1-SG02055.jpg
March 22 2016
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.
stem-cells.jpg
February 25 2016
Early 2016 looks to be data-rich for stem cell group ReNeuron as it progresses its clinical portfolio on multiple fronts.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.